DERMAdoctor’s Calm Cool + Corrected Eczema Balm Receives National Eczema Association Seal of Acceptance
December 13 2021 - 9:59AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
pharmaceutical company focused on developing and commercializing
high-quality, scientifically formulated products for the eyecare
and skincare markets, announces that DERMAdoctor’s Calm Cool +
Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair
Balm has received the National Eczema Association (NEA) Seal of
Acceptance™. The NEA Seal is granted in recognition of products
that meet the NEA’s rigorous standards for providing benefits and
improving the quality of life for people with eczema and sensitive
skin.
Calm Cool + Corrected Eczema + Dermatitis Clinical Repair Balm
is part of DERMAdoctor’s Calm Cool + Corrected line of skin
solutions, which were created to help soothe and comfort irritable
skin. It is formulated with high-potency,
dermatologist-recommended, eczema-active 1% colloidal oatmeal to
help temporarily protect and relieve minor skin irritations and
itching, together with an advanced complex of ceramides and
essential lipids to aid in repairing vital skin barrier function
and reduce moisture loss, and dermatologic botanicals that are rich
in skin reparative essential fatty acids.
“We are honored that Calm Cool + Corrected Eczema + Dermatitis
Clinical Repair Balm has been recognized with the NEA prestigious
Seal of Acceptance,” said Audrey Kunin, M.D., NovaBay’s Chief
Product Officer, DERMAdoctor co-founder and board-certified
dermatologist. “Eczema is a significant problem that afflicts an
estimated 31 million Americans, many of whom are children. Our
concentrated, soothing formula is suitable for head-to-toe use for
both adult and pediatric patients. Our goal at DERMAdoctor is to
ensure that when it comes to skincare, no problem is left
unaddressed.”
Dr. Kunin will feature Calm Cool + Corrected Eczema + Dermatitis
Clinical Repair Balm as an on-air guest on the QVC® network in
February 2022.
About the National Eczema Association
The National Eczema Association is a not-for-profit 501(c)(3)
organization with a mission to improve the health and quality of
life for individuals with eczema through research, support and
education. The NEA Seal further helps individuals recognize
products that are suitable for the care of eczema or sensitive
skin, empowering consumers to make informed purchase decisions to
help manage their conditions.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that
develops and sells scientifically created and clinically proven
consumer products for the eyecare and skincare markets. Avenova® is
the most prescribed antimicrobial lid and lash spray and CelleRx®
is a breakthrough product in the beauty category. In November 2021,
NovaBay acquired DERMAdoctor, LLC, a company commercializing more
than 30 dermatologist-developed skincare products sold through
traditional domestic retailers, digital beauty channels and
international distributors.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current product offerings, marketing efforts, and any
future revenue that may result from selling such products, as well
as generally the Company’s expected future financial results. These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or achievements to be
materially different and adverse from those expressed in or implied
by the forward-looking statements. Factors that might cause or
contribute to such differences include, but are not limited to,
risks and uncertainties relating to the size of the potential
market for our products, the integration of DERMAdoctor’s business
into the Company’s business, the possibility that the available
market for the Company’s products will not be as large as expected,
the Company’s products will not be able to penetrate one or more
targeted markets, and revenues will not be sufficient to meet the
Company’s cash needs. Other risks relating to NovaBay’s business,
including risks that could cause results to differ materially from
those projected in the forward-looking statements in this press
release, are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on
Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211213005735/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2024 to May 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From May 2023 to May 2024